Bilobetin
Based on 2 publication(s) in Google Scholar
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.71%
- No. CAS: 521-32-4
- Fòrmula: C31H20O10
- Peso molecular:552.48
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
MAPK Compound Library
HY-L010
-
Metabolism/Protease Compound Library
HY-L012
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
Glutamine Metabolism Compound Library
HY-L064
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Antidepressant Compound Library
HY-L108
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Nuclear Receptor Compound Library
HY-L126
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Bilobetin
More
Actividad biológica
|
PPARα |
PKA |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>50 μM
Compound: 12
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29921475] |
| HepG2 | IC50 |
>50 μM
Compound: 12
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29921475] |
| MCF7 | IC50 |
26.5 μM
Compound: 7
|
Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
|
[PMID: 34875389] |
| MGC-803 | IC50 |
>50 μM
Compound: 12
|
Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29921475] |
| T-24 | IC50 |
>50 μM
Compound: 12
|
Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29921475] |
Bilobetin (0-40 μM, 24/48/72 h) inhibits the cell proliferation in Huh7 and HepG2 cells[4].
Bilobetin (0-20 μM, 24 and 48 h) induces apoptosis and increases sub G1 population in Huh7 and HepG2 cells[4].
Bilobetin (0-20 μM, 24 h) induces accumulation of ROS and DNA damage in Huh7 and HepG2 cells[4].
Bilobetin (1-2 μM, 1 days) inhibits the phosphorylation of AKT in sebocytes[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Huh7 and HepG2 cells
-
Concentration:0, 2.5, 5, 10, 20, and 40 μM
-
Incubation Time:24/48/72 h
-
Result:Inhibited cell proliferation in a dose dependent manner, with IC50s of 18.28 μM at 48 h in Huh7 cells, and 19 μM at 72 h in HepG2 cells.
-
Cell Line:Huh7 and HepG2 cells
-
Concentration:0, 2.5, 5, 10, 20 μM
-
Incubation Time:24/48 h
-
Result:Showed the total apoptotic cell rate of 2.2, 2.2, 1.9, and 10.6% for 24 h (Huh7 cells) at 0, 5, 10, and 20 μM, and 1.7, 1.5, 7.5, and 22.5% for 48 h (Huh7 cells) at 0, 5, 10, and 20 μM.
Showed the total apoptotic cell rate of 1.1, 1.2, 1.6, and 3.0% for 24 h (Huh7 cells) at 0, 5, 10, and 20 μM, and 1.5, 1.1, 3.2, and 14.2% for 48 h (Huh7 cells) at 0, 5, 10, and 20 μM, respectively.
Bilobetin (i.p., 50 mg/kg, for 7 days) induces kidney injury in rats, and promotes the trafficking of AQP-2 onto the plasma membrane in rats[2].
Bilobetin (6 and 12 mg/kg, i.p., daily for ten days.) shows protective effects against Cisplatin (HY-17394) (7 mg/kg, i.p., a single dose on the third day)-induced testicular toxicity in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:rats fed a high-fat diet[1]
-
Dosage:12 mg/kg/day
-
Administration:i.p., 4 or 14 days after mice were fed a HFD for 8 weeks.
-
Result:Increased glucose infusion rate (GIR, P < 0.05) and reduced EGP (P < 0.05) in basal and clamp states.
Reduced total TG (P < 0.01) and VLDL-TG (P < 0.01).
Enhances hepatic Intralipid-TG uptake.
Reduced the total amount of lipid level in the liver and muscle.
Promoted the phosphorylation of PPARα and the translocation of PPARα from the cytoplasm to the nucleus in rats liver.
Chemical Information
-
No. CAS 521-32-4
-
Appearance Solid
-
Peso molecular 552.48
-
Fòrmula C31H20O10
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=C(O)C=C2)OC3=C(C4=CC(C5=CC(C6=C(O)C=C(O)C=C6O5)=O)=CC=C4OC)C(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
Solvente y solubilidad
DMSO : 125 mg/mL (226.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.76 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (288 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kou XH, et al. Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet. Br J Pharmacol. 2012 Apr;165(8):2692-706. [Content Brief]
[2]. Wang Q, et al. Bilobetin induces kidney injury by influencing cGMP-mediated AQP-2 trafficking and podocyte cell cycle arrest. Phytomedicine. 2019 Nov;64:153073. [Content Brief]
[3]. Negm WA, et al. The Mechanistic Perspective of Bilobetin Protective Effects against Cisplatin-Induced Testicular Toxicity: Role of Nrf-2/Keap-1 Signaling, Inflammation, and Apoptosis. Biomedicines. 2022 May 13;10(5):1134 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8100 mL | 9.0501 mL | 18.1002 mL | 45.2505 mL |
| 5 mM | 0.3620 mL | 1.8100 mL | 3.6200 mL | 9.0501 mL | |
| 10 mM | 0.1810 mL | 0.9050 mL | 1.8100 mL | 4.5251 mL | |
| 15 mM | 0.1207 mL | 0.6033 mL | 1.2067 mL | 3.0167 mL | |
| 20 mM | 0.0905 mL | 0.4525 mL | 0.9050 mL | 2.2625 mL | |
| 25 mM | 0.0724 mL | 0.3620 mL | 0.7240 mL | 1.8100 mL | |
| 30 mM | 0.0603 mL | 0.3017 mL | 0.6033 mL | 1.5084 mL | |
| 40 mM | 0.0453 mL | 0.2263 mL | 0.4525 mL | 1.1313 mL | |
| 50 mM | 0.0362 mL | 0.1810 mL | 0.3620 mL | 0.9050 mL | |
| 60 mM | 0.0302 mL | 0.1508 mL | 0.3017 mL | 0.7542 mL | |
| 80 mM | 0.0226 mL | 0.1131 mL | 0.2263 mL | 0.5656 mL | |
| 100 mM | 0.0181 mL | 0.0905 mL | 0.1810 mL | 0.4525 mL |
Powered by Bioz